Getty Images
Many estate planners believe that their job is done when the beneficiaries avoid probate and receive their inheritance. However, when beneficiaries receive their inheritance in their name outright, that needlessly exposes the legacy you leave to the claims of creditors,
Lucid Motors (NASDAQ:LCID) enjoyed a period of time where it had robust momentum, but that period has since faded. LCID stock is down about 70% from the highs in February, when the stock topped out near $65.
Source: ggTravelDiary / Shutterstock.com
Now near $20, L
Here's Advertisement
The stock of Five Below (NASDAQ:FIVE) is losing ground to a rising market this week. The stock had dropped 10% by 2 p.m. EDT Friday, compared to 0.2% boost in the S&P 500, according to data provided by S&P Global Market Intelligence.
The drop was sparked by a poorly received earnings report, yet the stock is still in positive territory so far in 2021.
The July 20 press release from Sundial Growers (NASDAQ:SNDL) announcing that it had closed its purchase of the Spiritleaf retail cannabis network didn’t do anything for SNDL stock.
Source: Postmodern Studio / Shutterstock.com
From July 20 throug
Shares of Globalstar (NYSEMKT:GSAT) rocketed 30% on Wednesday, as rumors of a potential deal with Apple (NASDAQ:AAPL) intensified.
So whatLate last month, respected analyst Ming-Chi Kuo posited that Apple's new iPhones will support satellite communications. Kuo postulat
The overall crypto market cap dropped by 2.47% to $2.02 trillion over the past seven days as Bitcoin (CRYPTO: BTC) failed to find support above $50,000.
What Happened: Even as several altcoins experienced steep corrections, on-chain analytics platform Santiment noted that Ethereum (CRYPT
Getty Images
Many estate planners believe that their job is done when the beneficiaries avoid probate and receive their inheritance. However, when beneficiaries receive their inheritance in their name outright, that needlessly exposes the legacy you leave to the claims of creditors,
Shares of ProQR Inc. (NASDAQ:PRQR), a clinical-stage biopharmaceutical company, soared 28% Thursday morning after announcing a new collaboration deal with Eli Lilly (NYSE:LLY). Excitement for the deal cooled off in the afternoon, and the stock finished the day 12.5% higher.
SoHere's Advertisement